Compare Corning Incorporated (GLW) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Corning Incorporated vs TG Therapeutics Inc — how do they compare? Corning Incorporated trades at $155.99 (market cap $150.10B), while TG Therapeutics Inc trades at $55.3 (market cap $8.64B). The key difference: Corning Incorporated is far larger — about 17.4× TG Therapeutics Inc's market cap, and Corning Incorporated pays a 0.64% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| GLW | TGTX | |
|---|---|---|
Market Cap | $150.10B | $8.64B |
Sector | Technology | Health |
52-Week High | $255.79 | $59.06 |
52-Week Low | $52.97 | $26.39 |
Enterprise Value | $158.27B | $8.88B |
Dividend Yield | 0.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLW is trading at $156.59, down 16.57% over 24 hours, reflecting a significant pullback from recent highs. The stock shows bearish technical signals but maintains strong fundamentals with revenue growth to $15.63 billion in 2025 and net income of $1.60 billion. Recent earnings beats and analyst optimism around AI-driven optical communication demand provide a positive backdrop despite near-term volatility.
The outlook for GLW is cautiously optimistic, with a consensus price target of $210.10 implying substantial upside. Key opportunities include partnerships with NVIDIA and Amazon in AI infrastructure, while risks involve high valuation multiples and sensitivity to tech sector sentiment. Long-term growth in 5G and automotive glass supports the investment case.
TG Therapeutics (TGTX) trades at $56.20, up 2.39% on the day, with a bullish technical signal and strong analyst consensus (84.6% buy ratings). The stock's momentum is supported by robust revenue growth, with 2025 revenue reaching $616.29M and net income of $447.18M, yielding impressive profitability margins (Gross Margin: 83.05%, ROE: 112.6%). Recent positive clinical updates for Briumvi in multiple sclerosis and schizophrenia trials have fueled investor optimism and media coverage.
The outlook remains positive due to Briumvi's commercial expansion and pipeline progress, though risks include earnings volatility (two recent misses), high valuation multiples (EV/EBITDA: 59.1), and clinical trial dependencies. The current price sits above the consensus price target of $48.50, suggesting near-term valuation concerns may limit upside unless operational execution continues to exceed expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
